Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)

Next Previous
Trial Profile

Neo-adjuvant Androgen Deprivation Therapy, Pelvic Radiotherapy and RADium-223 for new presentation T1-4 N0/1 M1B adenocarcinoma of prostate (ADRRAD Trial)

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 08 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Radium 223 chloride (Primary) ; Docetaxel; Goserelin; Leuprorelin; Leuprorelin; Triptorelin
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions
  • Acronyms ADRRAD

    • Most Recent Events

    • 29 Jun 2021 Results assessing safety and efficacy of combination of androgen deprivation therapy, up front docetaxel, radium-223 and external beam radiotherapy to prostate and pelvis in metastatic hormone sensitive prostate cancer, published in the Clinical Cancer Research.
    • 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium
    • 13 Feb 2020 According to Bayers media release, data from this trial will be presented at the 2020 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place February 13-15, 2020 in San Francisco, California.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top